About PAION

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.

 

PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).

 

PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia.

 

What does PAIONeering mean to us?  PAIONeering means engineering the medical future, forging new paths and setting benchmarks. We have short lines of communication that make it easy to take decisions and respond quickly. A true PAIONeer is not a lone warrior, but rather a committed team player who knows that the only way to achieve our ambitious goals is to do it together. We expect flexibility and a hands-on working style from our employees. There is no room for coveting status at PAION - our work is about responsibility, achievement and room for growth.

 

PAION AG is listed on the Frankfurt Stock Exchange (Prime Standardhttp://www.paion.com/ Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3).